IDH1 and glioblastoma: Therefore, these data suggest that SSAs exert antiproliferative effects on patient-derived primary GBM-cells, with different effects depending on IDH1 status and recurrence, opening new avenues to explore their potential as novel targeting therapy for patients with GBM from a personalized perspective.